
BLFS Valuation
BioLife Solutions Inc
- Overview
- Forecast
- Valuation
- Earnings
BLFS Relative Valuation
BLFS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BLFS is overvalued; if below, it's undervalued.
Historical Valuation
BioLife Solutions Inc (BLFS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.78 is considered Undervalued compared with the five-year average of -1566.12. The fair price of BioLife Solutions Inc (BLFS) is between 36.50 to 50.27 according to relative valuation methord. Compared to the current price of 24.34 USD , BioLife Solutions Inc is Undervalued By 33.32%.
Relative Value
Fair Zone
36.50-50.27
Current Price:24.34
33.32%
Undervalued
-3245.33
PE
1Y
3Y
5Y
Trailing
Forward
40.54
EV/EBITDA
BioLife Solutions Inc. (BLFS) has a current EV/EBITDA of 40.54. The 5-year average EV/EBITDA is 91.80. The thresholds are as follows: Strongly Undervalued below -132.63, Undervalued between -132.63 and -20.41, Fairly Valued between 204.01 and -20.41, Overvalued between 204.01 and 316.23, and Strongly Overvalued above 316.23. The current Forward EV/EBITDA of 40.54 falls within the Historic Trend Line -Fairly Valued range.
-450.58
EV/EBIT
BioLife Solutions Inc. (BLFS) has a current EV/EBIT of -450.58. The 5-year average EV/EBIT is -116.95. The thresholds are as follows: Strongly Undervalued below -1117.23, Undervalued between -1117.23 and -617.09, Fairly Valued between 383.20 and -617.09, Overvalued between 383.20 and 883.34, and Strongly Overvalued above 883.34. The current Forward EV/EBIT of -450.58 falls within the Historic Trend Line -Fairly Valued range.
10.78
PS
BioLife Solutions Inc. (BLFS) has a current PS of 10.78. The 5-year average PS is 8.87. The thresholds are as follows: Strongly Undervalued below 1.25, Undervalued between 1.25 and 5.06, Fairly Valued between 12.68 and 5.06, Overvalued between 12.68 and 16.50, and Strongly Overvalued above 16.50. The current Forward PS of 10.78 falls within the Historic Trend Line -Fairly Valued range.
43.59
P/OCF
BioLife Solutions Inc. (BLFS) has a current P/OCF of 43.59. The 5-year average P/OCF is 57.65. The thresholds are as follows: Strongly Undervalued below -161.66, Undervalued between -161.66 and -52.00, Fairly Valued between 167.31 and -52.00, Overvalued between 167.31 and 276.96, and Strongly Overvalued above 276.96. The current Forward P/OCF of 43.59 falls within the Historic Trend Line -Fairly Valued range.
481.63
P/FCF
BioLife Solutions Inc. (BLFS) has a current P/FCF of 481.63. The 5-year average P/FCF is 5.13. The thresholds are as follows: Strongly Undervalued below -984.30, Undervalued between -984.30 and -489.59, Fairly Valued between 499.84 and -489.59, Overvalued between 499.84 and 994.55, and Strongly Overvalued above 994.55. The current Forward P/FCF of 481.63 falls within the Historic Trend Line -Fairly Valued range.
BioLife Solutions Inc (BLFS) has a current Price-to-Book (P/B) ratio of 3.35. Compared to its 3-year average P/B ratio of 2.69 , the current P/B ratio is approximately 24.62% higher. Relative to its 5-year average P/B ratio of 3.28, the current P/B ratio is about 2.16% higher. BioLife Solutions Inc (BLFS) has a Forward Free Cash Flow (FCF) yield of approximately 0.93%. Compared to its 3-year average FCF yield of -1.73%, the current FCF yield is approximately -153.86% lower. Relative to its 5-year average FCF yield of -1.56% , the current FCF yield is about -159.88% lower.
3.35
P/B
Median3y
2.69
Median5y
3.28
0.93
FCF Yield
Median3y
-1.73
Median5y
-1.56
Competitors Valuation Multiple
The average P/S ratio for BLFS's competitors is 52.68, providing a benchmark for relative valuation. BioLife Solutions Inc Corp (BLFS) exhibits a P/S ratio of 10.78, which is -79.54% above the industry average. Given its robust revenue growth of 28.94%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BLFS decreased by 5.95% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -28.20 to -62.30.
The secondary factor is the Revenue Growth, contributed 28.94%to the performance.
Overall, the performance of BLFS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

DSP
Viant Technology Inc
9.500
USD
-0.31%

SCSC
Scansource Inc
42.600
USD
-2.96%

HROW
Harrow Inc
38.820
USD
-2.97%

MRVI
Maravai LifeSciences Holdings Inc
2.610
USD
+0.38%

FOXF
Fox Factory Holding Corp
29.610
USD
-0.20%

NVEE
NV5 Global Inc
22.140
USD
+0.49%

FVRR
Fiverr International Ltd
22.370
USD
+1.50%

TBLA
Taboola.com Ltd
3.320
USD
+0.91%

CNNE
Cannae Holdings Inc
17.810
USD
-0.45%

IMKTA
Ingles Markets Inc
64.170
USD
+0.64%
FAQ

Is BioLife Solutions Inc (BLFS) currently overvalued or undervalued?
BioLife Solutions Inc (BLFS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.78 is considered Undervalued compared with the five-year average of -1566.12. The fair price of BioLife Solutions Inc (BLFS) is between 36.50 to 50.27 according to relative valuation methord. Compared to the current price of 24.34 USD , BioLife Solutions Inc is Undervalued By 33.32% .

What is BioLife Solutions Inc (BLFS) fair value?

How does BLFS's valuation metrics compare to the industry average?

What is the current P/B ratio for BioLife Solutions Inc (BLFS) as of Aug 18 2025?

What is the current FCF Yield for BioLife Solutions Inc (BLFS) as of Aug 18 2025?

What is the current Forward P/E ratio for BioLife Solutions Inc (BLFS) as of Aug 18 2025?
